



08-18-06

ITW

CASE PD/4-32803A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV727274492 US

Express Mail Label Number

August 17, 2006

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1646

GRASSBERGER ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/003512

FILED: 2 APRIL 2004

U.S. APPLICATION NO: 10/550,355 ✓

35 USC §371 DATE: 3 NOVEMBER 2005

FOR: COMBINATION OF A MACROLIDE T-CELL IMMUNOMODULATOR  
AND A CALCIFEROL FOR THE TREATMENT OF SKIN DISEASES  
OR OF INFLAMMATORY BOWEL DISEASE

**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed September 23, 2005. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-2614

  
\_\_\_\_\_  
Gregory C. Houghton  
Attorney for Applicants  
Reg. No. 47,666

Date: 8/17/06

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

PD/4-32803A

APPLICATION NO.

10/550,355


APPLICANT

GRASSBERGER ET AL.

FILING DATE

NOVEMBER 3, 2005

Group



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	2004/087170	10/14/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Branisteanu et al., "Synergism Between Sirolimus and 1,25-dihydroxyvitamin D <sub>3</sub> in vitro and in vivo", Journal of Neuroimmunology 79, pp. 138-147 (1997).
	AS	Brainsteanu et al., "Combination of Vitamin D Analogues and Immunosuppressants", Clin. Immunother., Vol. 6, No. 6, pp. 465-478 (1996).
	AT	Mathieu et al., "Potential Role of 1,25(OH) <sub>2</sub> Vitamin D <sub>3</sub> as a Dose-Reducing Agent for Cyclosporine and FK 506", Transplantation Proceedings, Vol. 26, No. 6, p. 3130 (1994).


EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.  
PD/4-32803A  
APPLICATION NO.  
10/550,355  
APPLICANT  
GRASSBERGER ET AL.  
FILING DATE  
NOVEMBER 3, 2005

Group

EXAMINER  
INITIAL

**OTHER DOCUMENTS** (Including Abstract, Title, Date, Pertinent pages, Etc.)

DA	Ogawa et al., "Osteoblastic Differentiation is Enhanced by Rapamycin in Rat Osteoblast-like Osteosarcoma (ROS 17/2.8) Cells", Biochemical and Biophysical Research Communications, Vol. 249, pp. 226-230 (1998).
DB	van Etten et al., "Analogues of 1,25-Dihydroxyvitamin D3 as Dose-Reducing Agents for Classical Immunosuppressants <sup>1,2</sup> ", Transplantation, Vol. 69, No. 9, pp. 1932-1942 (2000).
DC	
DD	
DE	
DF	
DG	
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.